Immediate Impact
2 from Science/Nature 41 standout
Citing Papers
H2AX: A key player in DNA damage response and a promising target for cancer therapy
2024 Standout
Cystic fibrosis
2024 Standout
Works of Anna Chin being referenced
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele
2023 Standout
Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study
2023
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Anna Chin | 173 | 30 | 26 | 48 | 37 | 8 | 267 | |
| Christine Demangeat | 72 | 27 | 45 | 69 | 67 | 8 | 293 | |
| Kai Mi | 90 | 53 | 151 | 46 | 99 | 8 | 321 | |
| Bruce K. Rubin | 121 | 58 | 42 | 91 | 10 | 10 | 265 | |
| Kevin Boerner | 27 | 33 | 79 | 80 | 43 | 10 | 284 | |
| Nathaniel C. Myers | 184 | 18 | 71 | 25 | 47 | 11 | 330 | |
| Tewelde Berhane | 169 | 59 | 125 | 27 | 49 | 7 | 279 | |
| James Markowitz | 79 | 63 | 150 | 14 | 15 | 13 | 291 | |
| George Patrikakos | 26 | 35 | 69 | 29 | 25 | 10 | 265 | |
| S Shah | 60 | 56 | 132 | 27 | 44 | 8 | 261 | |
| H. Schäfer | 133 | 12 | 190 | 29 | 74 | 14 | 298 |
All Works
Loading papers...